fulvestrant

NDC 25021-471 · Sagent Pharmaceuticals

FDA carries 2 listing records for this NDC; the most recent is shown.

Generic namefulvestrant

Dosage formINJECTION, SOLUTION

RouteINTRAMUSCULAR

Active ingredient(s)FULVESTRANT

Strength50 mg/mL

Pharmacologic classEstrogen Receptor Antagonist [EPC], Estrogen Receptor Antagonists [MoA], Selective Estrogen Receptor Modulators [MoA]

Marketing categoryANDA

Packages

25021-471-66 — 2 SYRINGE in 1 CARTON (25021-471-66) / 5 mL in 1 SYRINGE

25021-471-74 — 2 SYRINGE in 1 CARTON (25021-471-74) / 5 mL in 1 SYRINGE

J9395 — Injection, fulvestrant, 25 mg Medicare Part B payment limit (ASP + 6%): $5.28

FDA lists these products with the same active ingredient.

0143-9022 — Fulvestrant, 0310-0720 — Fulvestrant, 0781-3532 — Fulvestrant, 0781-9055 — Fulvestrant, 16714-070 — fulvestrant, 16729-436 — Fulvestrant, 43598-262 — Fulvestrant, 55150-394 — Fulvestrant, 62332-650 — Fulvestrant, 63323-715 — Fulvestrant, 68001-484 — Fulvestrant, 68001-522 — Fulvestrant, 68001-626 — Fulvestrant, 68462-317 — Fulvestrant, 70121-1463 — Fulvestrant, 70700-284 — fulvestrant, 70710-1688 — fulvestrant, 70771-1626 — fulvestrant, 70860-211 — fulvestrant, 71288-555 — Fulvestrant, +3 more

From the FDA National Drug Code Directory, retrieved August 24, 2026. Product listings are submitted by labelers; FDA does not verify them.